Tesamorelin + Ipamorelin
FDA-approved GHRH drug used off-label in a fat-loss stack
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The combination has never been studied. There is no trial, no case series, and no animal work testing tesamorelin alongside ipamorelin, so any claim of synergy is inference from mechanism rather than evidence. What does exist is unusually good for one half of the pair. Tesamorelin's phase 3 program in HIV-associated lipodystrophy, published in the New England Journal of Medicine and its follow-on reports, showed visceral adipose tissue reductions of roughly 15 to 18 percent against placebo over 26 weeks, with regain after discontinuation. That result belongs to a specific population with a specific pathology, and it has not been reproduced as a general fat-loss finding in metabolically healthy adults. Ipamorelin's human record is thin. It raises growth hormone acutely, it was carried into postoperative ileus trials that did not lead to approval, and there is no published body-composition endpoint data of any weight. The theoretical argument for pairing them, that a GHRH analog and a secretagogue act on separate receptors and produce a larger pulse together, is reasonable pharmacology drawn from older GHRH plus GHRP co-administration studies. It has not been tested for this pair, and a larger GH pulse has never been shown to translate into better outcomes.
- FDA
- Tesamorelin is FDA-approved, but ONLY as Egrifta/Egrifta SV to reduce excess belly fat in people with HIV-associated lipodystrophy. Using it for general fat loss or anti-aging is off-label. Ipamorelin is not FDA-approved for anything, and the combination is not approved.
- WADA
- Prohibited
Reference only. Not medical advice.
What can go wrong
Tesamorelin's approved-use data give a clearer side-effect picture than most peptides: injection-site reactions, joint pain, swelling and fluid retention, muscle aches, and tingling or numbness are common, and it can raise insulin-like growth factor 1 (IGF-1) and blood sugar. The core growth-hormone risks apply: dose-dependent insulin resistance and higher blood sugar, fluid retention, and the theoretical concern that raising IGF-1 could accelerate existing or hidden tumors; tesamorelin's label specifically warns against use in people with active cancer. Adding Ipamorelin pushes growth hormone higher with no combination safety data. Off-label use moves the drug outside the population it was tested in (people with HIV), so the risk-benefit balance is less certain. Tesamorelin is also expensive, prohibited for competitive athletes, and Ipamorelin remains unapproved and unregulated in sourcing.
Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Tesamorelin + Ipamorelin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
This stack combines Tesamorelin, the only FDA-approved growth-hormone-releasing hormone (GHRH) analog, with Ipamorelin, a growth-hormone secretagogue. Tesamorelin is a synthetic version of GHRH (the natural signal that tells the pituitary gland to release growth hormone) that resists rapid breakdown in the body; it was approved in 2010 under the brand Egrifta to reduce excess belly fat in people with HIV-associated lipodystrophy (abnormal fat distribution linked to HIV treatment). In controlled trials for that approved use, tesamorelin cut visceral fat (the deep belly fat around organs) by roughly 15 to 18 percent versus placebo. Ipamorelin adds a second, ghrelin-mimicking trigger for growth-hormone release, on the same logic as the CJC-1295 pairing. Outside of HIV lipodystrophy, this combination is used off-label, meaning a doctor legally prescribes an approved drug for an unapproved purpose; the FDA has not approved tesamorelin for general fat loss, anti-aging, or growth-hormone deficiency. Because tesamorelin has real trial data behind its approved use, this stack has somewhat more evidence than the others here, though the two have not been studied together. It is promoted by anti-aging and metabolic clinics and telehealth platforms, and questioned by endocrinologists who note the off-label leap and the cost.
approved drug, off-label stack
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Safety in detail
Tesamorelin is approved only for HIV-associated lipodystrophy in the United States and Canada, and its European presence is negligible, so almost every cosmetic or metabolic use worldwide sits outside any licensed indication. Ipamorelin holds no approval in any jurisdiction and reaches users through compounding pharmacies or unregulated research-chemical vendors, where identity, purity, and endotoxin content are frequently unverified. Both fall under the WADA prohibited list as growth hormone secretagogues, banned at all times in and out of competition. What remains genuinely unknown is the combination itself: no dosing schedule has been validated, no interaction study exists, and there is no data on whether adding ipamorelin's ghrelin-receptor signal to chronic GHRH stimulation changes the glucose and IGF-1 picture that tesamorelin's own trials documented.
What people get wrong
Often saidMyth: Tesamorelin's FDA approval covers this fat-loss stack.
ActuallyReality: Tesamorelin is approved only for HIV-associated belly fat; general fat-loss and anti-aging use, and adding ipamorelin, are off label and untested as a pair.
Often saidMyth: An approved drug in the mix makes the stack safe.
ActuallyReality: The approval halo does not extend to the combination; growth-hormone risks and the label's cancer warning still apply.
Who profits, and who pushes back
U.S. Food and Drug Administration
Approved tesamorelin only for HIV-associated lipodystrophy; has not approved it for general fat loss, anti-aging, or GH deficiency, and warns against use in active cancer.
Endocrinologists (general)
Note that off-label use extends an HIV-population drug to untested groups and that the ipamorelin add-on lacks combination safety data.
American Medical Association
Cautions patients that many marketed peptide regimens outrun their evidence and need real medical oversight.
Theratechnologies
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Markets the approved HIV indication, not the off-label stack.
Anti-aging / metabolic clinics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Use it for visceral fat and optimization; cash-pay model.
Telehealth peptide platforms
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Often via compounding pharmacies.
Biohacker / longevity podcasters
Some disclose clinic ties; enthusiasm varies.
Where the research comes from
Most of the published research on this comes from one place. 58% of it is from North America. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| North America | 58% |
| Europe | 17% |
| Asia-Pacific | 13% |
| Latin America | 7% |
| Other | 5% |
Research published from: United States.
How we got here
Tesamorelin began as TH9507 at Theratechnologies in Montreal, a modified version of the full 44 amino acid human GHRH sequence carrying a trans-3-hexenoyl group that helps it survive enzymatic clipping long enough to reach the pituitary. Its clinical identity was built entirely inside HIV medicine, where a phase 3 program partnered with Serono and later EMD Serono produced the 2010 FDA approval of Egrifta, followed by the more stable Egrifta SV in 2019 and a further reformulation after that. Health Canada cleared it for the same narrow population. It never took hold in Europe, where no equivalent marketing authorisation was maintained. Ipamorelin arrived from a different direction, out of Novo Nordisk's late 1990s pentapeptide work on growth hormone secretagogues, and was later carried into human trials for postoperative ileus by Helsinn without ever reaching approval anywhere. Nobody paired the two molecules in a laboratory. The combination is a clinic invention, assembled by American anti aging and telehealth prescribers through the late 2010s who wanted tesamorelin's real visceral fat data sitting alongside a cheap compounded secretagogue. Forums shortened it to tesa plus ipa. No author, protocol, or founding publication stands behind the pairing.
Tesamorelin was developed by the Canadian company Theratechnologies and approved by the FDA in 2010 as Egrifta for HIV-associated lipodystrophy, with an improved Egrifta SV formulation approved in 2019 and a further formulation since. It is the full 44-amino-acid GHRH sequence with a chemical modification that resists breakdown. Ipamorelin came from Novo Nordisk's 1998 work. Pairing them for off-label body composition is a clinic and telehealth practice that grew in the late 2010s and 2020s; there is no formal protocol or named originator for the combination, so originator claims are unvalidated.
- 1998Ipamorelin described by Novo Nordisk team (Raun et al.)
- 2010FDA approves tesamorelin (Egrifta) for HIV-associated lipodystrophy
- 2019FDA approves Egrifta SV, an improved formulation
- Late 2010sOff-label tesamorelin-plus-ipamorelin stacks spread in anti-aging medicine
- 2024FDA reiterates ipamorelin is unapproved and not compoundable
- 2026Peptide market and off-label prescribing draw press scrutiny
At a glance
- Tesamorelin approved?
- Yes, HIV belly fat only
- Ipamorelin approved?
- No
- Visceral fat reduction (trials)
- About 15-18% vs placebo
- Stack tested together?
- No dedicated trials
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Tesamorelin + Ipamorelin. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
Tesamorelin (Egrifta) is FDA-approved solely to reduce excess abdominal fat in HIV-infected patients with lipodystrophy; no other indication is approved.
U.S. Food and Drug Administration
Growth hormone secretagogues and GHRH analogs, including tesamorelin and ipamorelin, are prohibited at all times under section S2 of the prohibited list.
In phase 3 trials in HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue by roughly 15 to 18 percent versus placebo over 26 weeks, with regain after stopping.
New England Journal of Medicine (Falutz et al., 2007) and subsequent phase 3 reports
Ipamorelin was characterised as a selective pentapeptide growth hormone secretagogue arising from Novo Nordisk research in the late 1990s.
European Journal of Endocrinology (Raun et al., 1998)
Ipamorelin was evaluated in human trials for postoperative ileus and did not achieve marketing approval in any jurisdiction.
Egrifta is authorised in Canada for the same HIV-associated lipodystrophy indication and no broader use.
Health Canada Drug Product Database
No registered or published study has evaluated tesamorelin and ipamorelin administered together for any endpoint.
Co-administration of a GHRH analog with a separate secretagogue produces a larger acute growth hormone pulse than either alone, the mechanistic rationale cited for this stack.
Endocrine literature on GHRH plus GHRP co-administration